BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.
|Videos|December 29, 2021
Managing Burnout as a Pharmacist and Helping Oncology Patients Move Forward
Burnout in pharmacy can be managed with the proper planning and the right techniques for your preference.
Advertisement
Pharmacy Times spoke with holistic oncology pharmacist Jenna Carmichael from Wobbly Arrow Wellness about how her wellness center differs from others in the field, burnout for pharmacists, and how patients can continue to move forward in life from their cancer treatments.
Advertisement
Related to this article
Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
A retrospective study from Japan found that oncology pharmacist assessment before medical examination was associated with higher rates of complete adverse event resolution in outpatient chemotherapy.
September’s hematology coverage examined a new definition of myeloma cure, patient preferences for treatment delivery, and emerging strategies for deepening responses.
September oncology coverage highlighted new breast and kidney cancer combinations, updated lung cancer labeling, and emerging evidence connecting antibiotic exposure with CAR T-cell outcomes.
In a FINE-HEART analysis, cancer history raised the risk of death and hospitalization but did not blunt finerenone's cardiovascular and kidney benefits.
A detailed LINKER-MM1 analysis found that cytokine release syndrome (CRS) with linvoseltamab occurred early, was predominantly low grade, and became less frequent with successive step-up and full doses.
Advertisement
Advertisement
Trending on Pharmacy Times
1
What the 2025-2030 Dietary Guidelines Mean for Heart Health
2
EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
3
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
4
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
5